Amphastar Pharmaceuticals (NASDAQ:AMPH) Rating Lowered to Hold at StockNews.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

A number of other equities analysts also recently commented on AMPH. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $63.00.

Amphastar Pharmaceuticals Trading Up 2.8 %

Shares of AMPH opened at $47.57 on Thursday. Amphastar Pharmaceuticals has a twelve month low of $36.56 and a twelve month high of $65.92. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82. The company’s fifty day simple moving average is $46.38 and its 200-day simple moving average is $42.96. The company has a market cap of $2.32 billion, a P/E ratio of 15.20, a P/E/G ratio of 0.88 and a beta of 0.83.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.75 by $0.10. The company had revenue of $182.39 million for the quarter, compared to the consensus estimate of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. As a group, analysts expect that Amphastar Pharmaceuticals will post 3.71 EPS for the current year.

Insider Activity

In related news, EVP Rong Zhou sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the transaction, the executive vice president now owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO William J. Peters sold 10,282 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total value of $454,772.86. Following the transaction, the chief financial officer now owns 94,103 shares of the company’s stock, valued at $4,162,175.69. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Rong Zhou sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the transaction, the executive vice president now owns 118,388 shares of the company’s stock, valued at approximately $5,724,059.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,383 shares of company stock worth $1,524,123. Corporate insiders own 27.10% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its stake in shares of Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $1,710,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $364,000. Cim LLC raised its holdings in shares of Amphastar Pharmaceuticals by 7.5% in the second quarter. Cim LLC now owns 10,016 shares of the company’s stock worth $401,000 after buying an additional 701 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth $388,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.